<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <committeeReports />
    <sponsors>
      <item>
        <state>IL</state>
        <firstName>MARK</firstName>
        <byRequestType />
        <middleName>STEVEN</middleName>
        <bioguideId>K000360</bioguideId>
        <identifiers>
          <gpoId>8285</gpoId>
          <bioguideId>K000360</bioguideId>
          <lisID>1647</lisID>
        </identifiers>
        <fullName>Sen. Kirk, Mark Steven [R-IL]</fullName>
        <lastName>KIRK</lastName>
        <party>R</party>
      </item>
    </sponsors>
    <recordedVotes />
    <policyArea>
      <name>Health</name>
    </policyArea>
    <titles>
      <item>
        <chamberCode />
        <titleType>Short Titles as Introduced</titleType>
        <chamberName />
        <title>REGROW Act</title>
        <parentTitleType />
      </item>
      <item>
        <chamberCode />
        <titleType>Short Titles as Introduced</titleType>
        <chamberName />
        <title>Reliable and Effective Growth for Regenerative Health Options that Improve Wellness</title>
        <parentTitleType />
      </item>
      <item>
        <chamberCode />
        <titleType>Official Title as Introduced</titleType>
        <chamberName />
        <title>A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.</title>
        <parentTitleType />
      </item>
      <item>
        <chamberCode />
        <titleType>Display Title</titleType>
        <chamberName />
        <title>REGROW Act</title>
        <parentTitleType />
      </item>
    </titles>
    <amendments />
    <createDate>2016-03-17T05:08:21Z</createDate>
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Administrative law and regulatory procedures</name>
          </item>
          <item>
            <name>Cell biology and embryology</name>
          </item>
          <item>
            <name>Department of Health and Human Services</name>
          </item>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Organ and tissue donation and transplantation</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <latestAction>
      <links />
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
      <actionDate>2016-03-16</actionDate>
    </latestAction>
    <summaries>
      <billSummaries>
        <item>
          <text><![CDATA[<p><b>Reliable and Effective Growth for Regenerative Health Options that Improve Wellness or the REGROW Act</b></p> <p>This bill amends the Public Health Service Act to require the Food and Drug Administration (FDA) to conditionally approve certain cellular therapeutic products without initiation of large-scale clinical trials. A conditionally approved cellular therapy may be marketed if certain conditions are met, including conditions on the source, processing, and function of the cells in the product.<br> <br> The sponsor of a conditionally approved cellular therapy must apply for approval of the product as a biological product within five years. Unless the FDA has decided not to approve the product, the product may be marketed during this five-year period and the FDA may permit continued marketing while the application is being reviewed.</p> <p>An individual administering a conditionally approved cellular therapy must inform the recipient regarding conditional approval.</p> <p>The premarket report for a medical device used for cellular therapy must include specified information regarding the preparation or delivery of the cellular therapy.</p> <p>The approval of a medical device that is a cellular therapy must be based on laboratory performance testing and not clinical trials.</p> <p>A medical device used for cellular therapy is subject to medical device classification. The FDA must not limit the use of these devices to only specific cell types unless unique to the use of the device.</p> <p>The Center for Biologics Evaluation and Research has primary jurisdiction for premarket review of combination products that act primarily through cellular components.</p> The Department of Health and Human Services must work with stakeholders to promote the development of standards for regenerative medicine products.]]></text>
          <updateDate>2016-03-16T04:00:00Z</updateDate>
          <actionDate>2016-03-16</actionDate>
          <name>Introduced in Senate</name>
          <actionDesc>Introduced in Senate</actionDesc>
          <lastSummaryUpdateDate>2016-12-05T18:05:00Z</lastSummaryUpdateDate>
          <versionCode>00</versionCode>
        </item>
      </billSummaries>
    </summaries>
    <introducedDate>2016-03-16</introducedDate>
    <cboCostEstimates />
    <congress>114</congress>
    <laws />
    <updateDate>2018-06-02T07:15:55Z</updateDate>
    <actions>
      <actionByCounts>
        <senate>2</senate>
      </actionByCounts>
      <item>
        <actionDate>2016-03-16</actionDate>
        <committee>
          <systemCode>sshr00</systemCode>
          <name>Health, Education, Labor, and Pensions Committee</name>
        </committee>
        <links />
        <sourceSystem>
          <name>Senate</name>
          <code>0</code>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <committee />
        <type>IntroReferral</type>
        <links />
        <text>Introduced in Senate</text>
        <actionDate>2016-03-16</actionDate>
        <actionCode>10000</actionCode>
      </item>
      <actionTypeCounts>
        <introducedInSenate>1</introducedInSenate>
        <referredToCommittee>1</referredToCommittee>
      </actionTypeCounts>
    </actions>
    <billType>S</billType>
    <billNumber>2689</billNumber>
    <relatedBills>
      <item>
        <congress>114</congress>
        <type>HR</type>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
        <latestTitle>REGROW Act</latestTitle>
        <number>4762</number>
        <latestAction>
          <text>Referred to the Subcommittee on Health.</text>
          <actionDate>2016-03-18</actionDate>
        </latestAction>
      </item>
    </relatedBills>
    <committees>
      <billCommittees>
        <item>
          <systemCode>sshr00</systemCode>
          <chamber>Senate</chamber>
          <name>Health, Education, Labor, and Pensions Committee</name>
          <type>Standing</type>
          <activities>
            <item>
              <date>2016-03-16T15:49:03Z</date>
              <name>Referred to</name>
            </item>
          </activities>
          <subcommittees />
        </item>
      </billCommittees>
    </committees>
    <calendarNumbers />
    <originChamber>Senate</originChamber>
    <version>1.0.0</version>
    <cosponsors>
      <item>
        <fullName>Sen. Manchin, Joe, III [D-WV]</fullName>
        <bioguideId>M001183</bioguideId>
        <middleName />
        <firstName>Joe</firstName>
        <state>WV</state>
        <lastName>Manchin</lastName>
        <sponsorshipWithdrawnDate />
        <identifiers>
          <bioguideId>M001183</bioguideId>
          <lisID>1983</lisID>
          <gpoId>8256</gpoId>
        </identifiers>
        <party>D</party>
        <sponsorshipDate>2016-03-16</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <fullName>Sen. Collins, Susan M. [R-ME]</fullName>
        <bioguideId>C001035</bioguideId>
        <middleName>MARGARET</middleName>
        <firstName>SUSAN</firstName>
        <state>ME</state>
        <lastName>COLLINS</lastName>
        <sponsorshipWithdrawnDate />
        <identifiers>
          <lisID>1541</lisID>
          <bioguideId>C001035</bioguideId>
          <gpoId>8291</gpoId>
        </identifiers>
        <party>R</party>
        <sponsorshipDate>2016-03-16</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <notes />
    <title>REGROW Act</title>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

